Clinical trials: Transplant Patients
Inherited Metabolic Disorders (IMD)
A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456
A follow-up study to evaluate the safety and clinical outcomes of patients with inherited metabolic disorders (IMD) who have undergone hematopoietic stem cell transplantation (HSCT) with MGTA-456
- Trial name
- IMD-002 (NCT04008849)
- Testing
- Safety and efficacy assessments
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Magenta Therapeutics, Inc.
Renal Transplant
Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107
Aim of study is to provide safety and tolerability data on enteric-coated mycophenolate sodium in regard to adverse events, serious adverse events and patient and graft survival.
- Trial name
- NCT00149916
- Testing
- Mycophenolate sodium (enteric coated)
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis
The primary objective of this trial is to evaluate the clinical efficacy and safety of two oral doses of MP1032 (150 mg bid and 300 mg bid) when taken for 12 weeks by patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT03706209
- Testing
- MP1032
- Where
- 19 sites in Germany, Poland
- Volunteers
- 155 people
- Sponsor
- MetrioPharm AG
Multiple Myeloma
A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain
This is an observational, post-authorization, retrospective, multicenter study (PAS-OD) that will be conducted in approximately 20 centers in Spain.
- Trial name
- RETRO (NCT03602755)
- Where
- 20 sites in Spain
- Volunteers
- 706 people
- Sponsor
- Celgene
Hematologic Malignancies
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
This study is an open-label randomized, prospectively and historically controlled trial of the safety and efficacy of a single ProHema-CB unit used as part of a double CB transplant following myeloablative or reduced intensity…
- Trial name
- NCT01627314
- Testing
- ProHema-CB, Untreated CB
- Where
- 11 sites in United States
- Volunteers
- 62 people
- Sponsor
- Fate Therapeutics
Kidney Transplantation
A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients
This study will compare kidney function in kidney transplant patients following treatment with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine).
- Trial name
- NCT00048152
- Testing
- Corticosteroids, Neoral, Zenapax
- Where
- 36 sites in United States, Australia and 10 more
- Volunteers
- 539 people
- Sponsor
- Hoffmann-La Roche
Kidney Maintenance Transplant
Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)
The purpose of this study is to assess the impact that GI complaints have on patient reported outcomes in renal transplant recipients and to determine if there is improvement in patient reported outcomes when patients are…
- Trial name
- NCT00150007
- Testing
- Enteric-coated Mycophenolate sodium (EC-MPS)
- Volunteers
- 335 people
- Sponsor
- Novartis Pharmaceuticals
Bone Loss
A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.
The purpose of the study was to evaluate the effect of Pamidronate on bone mineral density loss and fracture rates up to 2 years, in post renal-transplant subjects on a Ciclosporin A and glucocorticoid based immunosuppressive…
- Trial name
- SMART (NCT00738257)
- Testing
- Pamidronate
- Where
- United Kingdom
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplantation
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant
The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.
- Trial name
- NCT00099736
- Testing
- FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids, FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids, MMF 2 g + full-dose Neoral (FDN) + corticosteroids
- Where
- 42 sites in United States
- Volunteers
- 696 people
- Sponsor
- Novartis Pharmaceuticals
Cervical Spondylosis, Cervical Radiculopathy
Evaluation of DTRAX Graft in Patients With Cervical Degenerative Disc Disease
DTRAX Graft is used to relieve nerve pressure in the neck in order to provide relief for Cervical Degenerative Disc Disease. This study is being conducted to determine the effectiveness of the graft, and to find out whether or…
- Conditions
- Cervical Spondylosis, Cervical Radiculopathy, Cervical Degenerative Disc Disease
- Trial name
- NCT01616719
- Testing
- DTRAX Graft
- Where
- 2 sites in United States
- Sponsor
- Providence Medical Technology, Inc.
Heart Transplant
Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
The purpose of this study is to evaluate the efficacy and safety of lower dose calcineurin inhibitors (CNI) in combination with Everolimus in Korean heart transplant recipients.
- Trial name
- OPTIMIZE-HTx (NCT06942156)
- Testing
- Everolimus, Mycophenolate mofetil Tablet/Capsule
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Sickle Cell Disease
Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)
This study evaluated a genome-edited, autologous, hematopoietic stem and progenitor cell (HSPC) product - OTQ923 to reduce the biologic activity of BCL11A, increasing fetal hemoglobin (HbF) and reducing complications of sickle…
- Trial name
- NCT04443907
- Testing
- OTQ923
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Venous Stenosis, Venous Occlusion
The Merit WRAPSODY™ Endovascular Stent Graft
This is a phase 1 study, designed to evaluate the safety and effectiveness of the WRAPSODY Stent Graft for the treatment of venous outflow circuit obstructions in the veins of the arm or thoracic central veins of subjects who…
- Trial name
- NCT03644017
- Testing
- WRAPSODY Stent Graft Placement
- Where
- 3 sites in Greece, United Kingdom
- Volunteers
- 46 people
- Sponsor
- Merit Medical Systems, Inc.
ESRD (End-Stage Renal Disease), Kidney Transplantation
Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
The purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ…
- Conditions
- ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
- Trial name
- EXPAND (NCT06878560)
- Testing
- 10 GE Xenokidney
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- United Therapeutics
Prophylaxis Of Invasive Fungal Infections
Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
To prevent recurrence of invasive fungal infection in patients with allogeneic stem cell transplants
- Trial name
- VOSIFI (NCT00143312)
- Testing
- voriconazole
- Where
- 17 sites in Belgium, France and 6 more
- Volunteers
- 45 people
- Sponsor
- Pfizer
Limbal Stem Cell Deficiency
Multicenter Study of CAOMECS Transplantation to Patients With Total Limbal Stem Cell Deficiency
This clinical study is a scientific study on patients who do not have any limbal stem cells. In this clinical study tissue is taken from the inside of the mouth, and cells from that tissue (epithelial cells) will be grown to form…
- Trial name
- NCT01489501
- Testing
- Surgical transplantation of CAOMECS to the ocular surface
- Where
- Germany
- Sponsor
- CellSeed France S.A.R.L.
Alcoholic Liver Cirrhosis
Long-Term Follow-up of Patients With Alcoholic Liver Cirrhosis Treated With Cellgram-LC
The goal of this observational study is to learn about the long-term safety of Cellgram-LC in patients with alcoholic liver cirrhosis who previously received Cellgram-LC in the PMC-P-07 study.
- Trial name
- NCT05093881
- Where
- 14 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Pharmicell Co., Ltd.
Organ or Tissue Transplant; Complications
Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients
Open-label, multicentre, randomized clinical trial to compare the pharmacokinetics of ENVARSUS® tablets and ADVAGRAF® capsules administered once daily in adult de-novo kidney transplant patients.
- Trial name
- NCT02500212
- Testing
- ENVARSUS®, ADVAGRAF®
- Where
- 7 sites in France
- Volunteers
- 75 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Hodgkin's Lymphoma
A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)
The primary objective was to provide drug to ongoing patients who were receiving panobinostat and to characterize the safety and tolerability of panobinostat in patients with HL after achieving a complete response following…
- Trial name
- PATH (NCT01034163)
- Testing
- Panobinostat
- Where
- 35 sites in United States, Australia and 12 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic
Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)
Post-authorisation observational study to assess the evolution in normal clinical practice of patients recently diagnosed with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukaemia (CMML), depending on the moment…
- Trial name
- NCT02085798
- Testing
- Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion
- Where
- 50 sites in Spain
- Volunteers
- 503 people
- Sponsor
- Celgene